PharmaTher Holdings Ltd.
PHRM
CNSX
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.48% | 0.82% | -15.26% | -13.58% | -17.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.61% | -51.73% | -64.41% | -65.76% | -51.22% |
| Operating Income | 26.61% | 51.73% | 64.41% | 65.76% | 51.22% |
| Income Before Tax | 28.42% | 52.66% | 66.85% | 69.24% | 64.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.42% | 52.66% | 66.85% | 69.24% | 64.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.42% | 52.66% | 66.85% | 69.24% | 64.12% |
| EBIT | 26.61% | 51.73% | 64.41% | 65.76% | 51.22% |
| EBITDA | 42.36% | 51.74% | 64.41% | 65.75% | 51.21% |
| EPS Basic | 29.44% | 53.05% | 67.12% | 69.27% | 64.07% |
| Normalized Basic EPS | 22.55% | 50.00% | 63.54% | 65.40% | 50.00% |
| EPS Diluted | 29.44% | 53.05% | 67.12% | 69.27% | 64.07% |
| Normalized Diluted EPS | 22.55% | 50.00% | 63.54% | 65.40% | 50.00% |
| Average Basic Shares Outstanding | 0.91% | 0.33% | 0.36% | 0.26% | 0.16% |
| Average Diluted Shares Outstanding | 0.91% | 0.33% | 0.36% | 0.26% | 0.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |